Gabriel Morris compensation by year
Immix Biopharma Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $100,000 | $425,000 | $446,000 | $475,000 | $475,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $1,135,750 | $0 | $0 | $0 |
| Option awards | $362,091 | $582,895 | $460,881 | $554,658 | $592,854 |
| Non-equity incentive | $0 | $212,500 | $223,000 | $237,500 | $285,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $0 |
| Total | $462,091 | $2,356,145 | $1,129,881 | $1,267,158 | $1,352,854 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immix Biopharma, Inc. DEF 14A filed April 6, 2026, accession 0001493152-26-015320, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Immix Biopharma, Inc. filed document, accession 0001493152-26-015320. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 212,500 | — | $2.04 |
| Option | 36,458 | — | $2.64 |
| Option | 122,083 | — | $1.86 |
| Option | 297,500 | — | $2.24 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Immix Biopharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Immix Biopharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Ilya Rachman | Chief Executive Officer, Chief Scientific Officer and Chairman | $1,352,854 |
| Gabriel Morris · this page | Chief Financial Officer, President and Director | $1,352,854 |
Board service
Immix Biopharma board · FY2021–FY2025How this board is paid
Company policy: Immix Biopharma pays directors a $40,000 cash retainer and $80,000 in Options. As stated in Immix Biopharma's FY2025 proxy.
Gabriel Morris's compensation dossier, Immix Biopharma
You have read Gabriel Morris's totals and holdings. The dossier adds each equity grant Immix Biopharma disclosed for Gabriel Morris and Immix Biopharma's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Immix Biopharma compensation record
free company briefThis page is one person within Immix Biopharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Immix Biopharma's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immix Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order IMMX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.